Navigation Links
ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
Date:12/6/2013

CAMBRIDGE, Mass., Dec. 6, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease. The research partnership will explore a human monoclonal antibody that targets misfolded superoxide dismutase 1 (SOD1). Misfolded SOD1 accumulates in familial and sporadic ALS, suggesting a generalized role as a drug target for ALS treatments.

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

"We are excited by the results of Neurimmune's findings," says Steve Perrin, Ph.D., CEO & CSO of ALS TDI. "Recent evidence would suggest that therapies targeting misfolded SOD1 could be important in both sporadic and familial forms of ALS. It is crucial that we use every tool available to us to advance potential treatments toward the clinic, and we are proud to work together with Neurimmune to attempt to do just that."

The collaboration will explore the high-affinity human antibodies developed by Neurimmune that selectively target misfolded SOD1. In preclinical studies with transgenic mice, chronic antibody treatment significantly reduced SOD1 pathology and rescued spinal cord motor neurons, resulting in significantly reduced muscle atrophy, better motor functions and increased survival. Neurimmune will present the key findings of their approach at the International Symposium on ALS/MND Research in Milan, Italy on December 7, 2013.

"ALS is a devastating neuromuscular disease,
'/>"/>

SOURCE ALS Therapy Development Institute
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Gene Therapy - Technologies, Markets and Companies
2. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
3. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. Squamous Cell Cancer Responds to SPDT Therapy
6. Stem cell therapy reverses diabetes
7. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
8. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
9. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015  Pomerantz LLP announces that a class ... ("Puma" or the "Company")(NYSE: PBYI ) and certain ... States District Court, Central District of California ... of a class consisting of all persons or entities ... May 13, 2015 inclusive (the "Class Period").  This class ...
(Date:7/2/2015)... 2015 College of DuPage students Sam ... invaluable real-world experiences while serving biophysics internships at the ... The students will be working as a part of ... at IIT. The internship came about from a discussion ... Dr. Kathy Finan , Biology; and Dr. Wereszczynski ...
(Date:7/2/2015)... ALTO, Calif. (PRWEB) , ... July 02, 2015 , ... ... to improve an individual’s quality of sleep, launched its Indiegogo campaign on June 23. ... functionality: Luzi's voice command technology makes it effortless to use, while the integration of ...
(Date:7/1/2015)... TRIANGLE PARK, N.C. and ... agricultural research firm AgBiome, and Genective, key developer ... to accelerate the discovery of new generations of ... traits for insect control to counter the realities ... partner with Genective, aligning AgBiome,s unique insect control ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4COD Students Participate in Prestigious Summer Internships 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2
... , KENILWORTH, N.J., Aug. 26 Schering-Plough ... European Medicines Agency (EMEA) has validated (accepted for review) the ... mometasone furoate and formoterol fumarate for the maintenance treatment of ... The company also announced today that the EMEA has validated ...
... N.C., Aug. 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... New York on Sept. 9 and Zurich on Sept. 10, 2009. ... Division and Government Affairs, will present at the Rodman & Renshaw ... at 2:00 p.m. eastern time. , , A ...
... , ... Trusted LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons directory service and website ... to improve their vision and find a highly qualified eye surgeon who can ... apart is a unique screening process ensuring that only those who are among ...
Cached Biology Technology:Schering-Plough Announces Two European Filings 2Schering-Plough Announces Two European Filings 3Schering-Plough Announces Two European Filings 4Schering-Plough Announces Two European Filings 5Schering-Plough Announces Two European Filings 6Schering-Plough Announces Two European Filings 7Schering-Plough Announces Two European Filings 8Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich 2LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 2LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 3LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 4LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 5LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 6LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 7
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards has ... sensors in the company,s portfolio from one of its module ... to mainly take place during the third quarter 2015. The ... Asia . Jörgen Lantto, CEO of FPC, ... the   growing interest from smartphone OEMs in integrating touch ...
(Date:6/15/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces that its leading payment security technology, the ... Experience! @ NYC June 18th. Digital Experience! @ ... in technology to over 300 of the top media covering ... Pavilion in New York City from ...
(Date:6/9/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, will be providing demonstrations of its ... Drug Information Association (DIA) Annual Meeting in ... will include previews of many exciting new enhancements that ... iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... Researchers have teased out the molecular process that can ... kills thousands each year who suffer battlefield casualties, heart ... an article published in the January edition of ... the enormously complex biomechanics of a reaction first observed ...
... The National Institute of Allergies and Infectious Diseases (NIAID), ... awarded a five-year contract totaling $15,254,919 to Tulane University ... fever, an often deadly viral disease that threatens hundreds ... is classified as a potential bioterrorism threat. The ...
... Iowa -- A previous six-month study by Iowa State ... soy protein, rich in isoflavones, lessened lumbar spine bone ... three-year study by some of those same researchers does ... ingested soy isoflavone tablets, except for a modest effect ...
Cached Biology News:Research could lead to way to halt deadly immune response 2Research could lead to way to halt deadly immune response 3Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 2Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 3
... constitute the principal excitatory neurotransmitter ... of glutamate receptors exist: Ionotropic ... glutamate receptors are oligomeric complexes ... KAI-2) which comprise ligand-gated calcium ...
... with motorized heated lid and skirted inner lid ... microarrays and chips. The four screw-down points allow ... of the motorized lid is set with software ... This interchangeable Moto Alpha unit functions on any ...
Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
... bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. ... CHAPSO. Has reduced electrostatic interactions that do ... DEAE-cellulose. Aggregation number: 8-16. Purity: ≥95% ... O. Aggregation number 8 - 16, CMC ...
Biology Products: